Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

ith the FDA a possible Phase 3 registration trial evaluating first-line docetaxel with and without OGX-011 and the strategy of combining the first-line registration trial with one of the second-line clinical trials for product marketing approval for patients with CRPC. - Secure a development and commercialization partnership for OGX-011 in 2009. - Report data from our ongoing Phase 1 clinical trial evaluating OGX-427 as a monotherapy in patients with solid tumors; these data have been selected for presentation at the American Society of Clinical Oncology 2009 Annual Meeting in the second quarter. - Initiate an investigator-sponsored Phase 1 clinical trial evaluating OGX-427 as a treatment in patients with bladder cancer, in the second quarter.

Financial Results

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of the OncoGenex Pharmaceuticals thereafter.

Research and development expenses for the fourth quarter and year ended December 31, 2008 were $4.2 million and $7.8 million, respectively, compared to $1.1 million and $4.1 million, respectively, in the corresponding periods of 2007. The increases in 2008 were primarily due to manufacturing costs incurred in the fourth quarter of 2008 associated with the development of our product candidate OGX-427, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus.

General and administrative expenses for the fourth quarter and year ended December 31, 2008 were $1.0 million and $3.3 million, respectively, compared to $0.8 million and $3.5 million, respectively, in the corresponding periods of 2007. The increase for the fourth quarter of
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Ophthalmic drug delivery ... and challenging endeavors as the anatomy, physiology and ... to the foreign substances. Ocular drug delivery technologies ... medication and minimal use of needles; also it ... and provides specific targeting within the ocular globe. ...
(Date:8/22/2014)... Nerium International, the go-to, buzzworthy ... spotlight again. Nerium will showcase its signature NeriumAD® ... Contouring Cream to Hollywood’s elite at the official ... 66th Primetime Emmy® Awards. , Developed from cutting-edge ... trials show that NeriumAD night cream dramatically reduces ...
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
(Date:8/21/2014)... SPRING, N.Y. , Aug. 21, 2014 /PRNewswire/ ... the launch of their Nutraceutical "TELO-20 for Dogs" ... and only Telomere-lengthening supplement in the world for ... ends of every chromosome in the body. A ... world,s leading experts in Telomere Science and Aging, ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... -- PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that its financial ... released on Thursday, May 14, 2009.PharmAthene management will be ... 2009 financial results. The call is scheduled to ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced its financial ... a net loss for the first quarter of 2009 of $10.9 ... Company,s expectations. This compares to a net loss for the ... Research and development expenses in the first quarter of 2009 ...
... DNDN ) today announced that management will present at the ... Merrill Lynch 2009 Health Care Conference, The New York ... 9:20 a.m. ET, Deutsche Bank Securities 34th Annual Healthcare ... 2009, 4:35 p.m. ET, Leerink Swann ...
Cached Biology Technology:Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 5
(Date:8/21/2014)... LAWRENCE A study recently published in the journal ... Kansas shows a new role for the protein adenomatous ... second-leading cause of cancer-related deaths in the U.S. , ... of Molecular Biosciences and co-leader of the Cancer Biology ... better part of her career trying to understand the ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
(Date:8/21/2014)... developed a novel and versatile modeling strategy to simulate ... materials as well as for studying polyelectrolytes, including DNA ... model much larger and more complex polyelectrolyte systems, and ... lead author of a paper on the work and ... Science and Engineering. "This is a big step forward ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... liver disease, extent of tissue damage depends on the balance ... new liver cells. In a significant minority of people who ... form scars. This can progress to chronic liver disease and ... unable to clean blood or produce vital hormones and clotting ...
... a type of cell that can be activated by tissues ... attack our own molecules, cells and organs, UCSF researchers have ... new strategies for fighting a range of autoimmune diseases ... and cells within us as well as for preventing ...
... CHICAGO A low-calorie diet eliminates insulin dependence ... with type 2 diabetes, according to a study presented ... of North America (RSNA). "Lifestyle interventions may have ... patients," said the study,s lead author, Sebastiaan Hammer, M.D., ...
Cached Biology News:The immune system has protective memory cells, researchers discover 2The immune system has protective memory cells, researchers discover 3Restricted calorie diet improves heart function in obese patients with diabetes 2